Syros Pharmaceuticals Inc logo

Syros Pharmaceuticals Inc

NAS:SYRS (USA)  
$ 5.11 +0.1 (+2%) 10:09 PM EST
At Loss
P/B:
8.88
Market Cap:
$ 136.58M
Enterprise V:
$ 87.01M
Volume:
135.71K
Avg Vol (2M):
180.93K
Also Trade In:
Volume:
135.71K
At Loss
Avg Vol (2M):
180.93K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Syros Pharmaceuticals Inc ( ) from 2016 to Jun 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Syros Pharmaceuticals stock (SYRS) PE ratio as of Jun 01 2024 is 0. More Details

Syros Pharmaceuticals Inc (SYRS) PE Ratio (TTM) Chart

To

Syros Pharmaceuticals Inc (SYRS) PE Ratio (TTM) Historical Data

Total 1246
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Syros Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-01 At Loss 2024-04-01 At Loss
2024-05-31 At Loss 2024-03-29 At Loss
2024-05-30 At Loss 2024-03-28 At Loss
2024-05-29 At Loss 2024-03-27 At Loss
2024-05-28 At Loss 2024-03-26 At Loss
2024-05-27 At Loss 2024-03-25 At Loss
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss

Syros Pharmaceuticals Inc (SYRS) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.